Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00567203 | A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia | PHASE1 | COMPLETED | 36 | — | — | Nov 1, 2007 | May 1, 2008 | Oct 2, 2008 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-3463275 | DRUG | PF-3463275 10mg |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Diagnosis of schizophrenia * In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months * Stable symptoms of schizophrenia for at least 3 months. Exclusion Criteria: * Subjects with a psychiatric disorder ot...